{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T15:54:30Z","timestamp":1772726070992,"version":"3.50.1"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T00:00:00Z","timestamp":1622419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Basic Research Program of China","doi-asserted-by":"publisher","award":["2016YFA0101001"],"award-info":[{"award-number":["2016YFA0101001"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p><jats:bold>Objectives:<\/jats:bold> Evidence has shown that angiotensin-converting enzyme 2 (ACE2), which can be upregulated after angiotensin-converting enzyme inhibitor (ACEi) and angiotensin receptor blocker (ARB) treatment, may play a dual role in the pathogenesis and progression of coronavirus disease 2019 (COVID-19). We aimed to assess the association between the use of ACEi\/ARB and the outcome of COVID-19 patients with preexisting hypertension in non-endemic areas.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> From January 17, 2020, to February 19, 2020, 286 patients with hypertension were enrolled in this retrospective study out of 1,437 COVID-19 patients from 47 centers in Zhejiang and Jiangsu Province. The composite endpoints consisted of mechanical ventilation, intensive care unit (ICU) admission, or death. Cox proportional hazards analysis was performed to assess the association between ACEi\/ARB and clinical outcomes of COVID-19 patients with hypertension.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> In the main analysis, 103 patients receiving ACEi\/ARB were compared with 173 patients receiving other regimens. Overall, 44 patients (15.94%) had an endpoint event. The risk probability of crude endpoints in the ACEi\/ARB group (12.62%) was lower than that in the non-ACEi\/ARB group (17.92%). After adjusting for confounding factors by inverse probability weighting, the results showed that the use of ACEi\/ARB reduced the occurrence of end events by 47% [hazard ratio (HR) = 0.53; 95% CI, 0.34\u20130.83]. Similar results were obtained in multiple sensitivity analyses.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> In this retrospective study, among COVID-19 patients with hypertension, the use of ACEi\/ARB is not associated with an increased risk of disease severity compared with patients without ACEi\/ARB. The trends of beneficial effects of ACEi\/ARB need to be further evaluated in randomized clinical trials.<\/jats:p>","DOI":"10.3389\/fcvm.2021.577398","type":"journal-article","created":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T05:22:45Z","timestamp":1622438565000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Association of ACEi\/ARB Use and Clinical Outcomes of COVID-19 Patients With Hypertension"],"prefix":"10.3389","volume":"8","author":[{"given":"Jing","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaowei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feifei","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyu","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiaoling","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinfeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongcui","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lanjuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,5,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1001\/jamacardio.2020.1624","article-title":"Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China","volume":"5","author":"Li","year":"2020","journal-title":"JAMA Cardiol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1186\/s13054-017-1882-z","article-title":"Recombinant human ACE2: acing out angiotensin II in ARDS therapy","volume":"21","author":"Zhang","year":"2017","journal-title":"Crit Care."},{"key":"B3","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/S2213-2600(20)30116-8","article-title":"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?","volume":"8","author":"Fang","year":"2020","journal-title":"Lancet Respir Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/nm1267","article-title":"Penninger: a crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury","volume":"11","author":"Kuba","year":"2005","journal-title":"Nat Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1161\/HYPERTENSIONAHA.120.15622","article-title":"Comparative impacts of angiotensin converting enzyme inhibitors versus angiotensin II receptor blockers on the risk of COVID-19 mortality","volume":"76","author":"Zhou","year":"2020","journal-title":"Hypertension"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e142","DOI":"10.1161\/CIRCRESAHA.120.317242","article-title":"Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin ii receptor blockers with mortality among patients with hypertension hospitalized with COVID-19","volume":"126","author":"Zhang","year":"2020","journal-title":"Circ Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1053\/j.gastro.2020.05.034","article-title":"Associations between angiotensin converting enzyme inhibitors and angiotensin ii receptor blocker use, gastrointestinal symptoms, and mortality among patients with COVID-19","volume":"159","author":"Tan","year":"2020","journal-title":"Gastroenterology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1093\/cid\/ciaa624","article-title":"Association of renin-angiotensin-aldosterone system inhibitors with COVID-19-related outcomes in Korea: a nationwide population-based cohort study","volume":"71","author":"Jung","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.120.15143","article-title":"Effects of ARBs and ACEIs on virus infection, inflammatory status and clinical outcomes in COVID-19 patients with hypertension: a single center retrospective study","volume":"76","author":"Yang","year":"2020","journal-title":"Hypertension"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1001\/jamacardio.2020.1855","article-title":"Association of use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with testing positive for coronavirus disease 2019 (COVID-19)","volume":"5","author":"Mehta","year":"2020","journal-title":"JAMA Cardiol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.jjcc.2020.10.015","article-title":"Lack of association of antihypertensive drugs with the risk and severity of COVID-19: a meta-analysis","volume":"77","author":"Ren","year":"2020","journal-title":"J Cardiol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"104927","DOI":"10.1016\/j.phrs.2020.104927","article-title":"ACEI\/ARB use and risk of infection or severity or mortality of COVID-19: a systematic review and meta-analysis","volume":"158","author":"Zhang","year":"2020","journal-title":"Pharmacol Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.jinf.2020.05.056","article-title":"Sheng: COVID-19 is more severe in patients with hypertension; ACEI\/ARB treatment does not influence clinical severity and outcome","volume":"81","author":"Hu","year":"2020","journal-title":"J Infect."},{"key":"B15","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1002\/jmv.26315","article-title":"Efficacy of ACEIs\/ARBs vs CCBs on the progression of COVID-19 patients with hypertension in Wuhan: a hospital-based retrospective cohort study","volume":"93","author":"Liu","year":"2021","journal-title":"J Med Virol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1093\/cid\/ciaa199","article-title":"Clinical characteristics of imported cases of COVID-19 in Jiangsu Province: a multicenter descriptive study","volume":"71","author":"Wu","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1101\/2020.02.06.20020974","article-title":"China medical treatment expert group for: clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"5749","DOI":"10.1038\/s41467-020-19478-2","article-title":"Collider bias undermines our understanding of COVID-19 disease risk and severity","volume":"11","author":"Griffith","year":"2020","journal-title":"Nat Commun."},{"key":"B19","doi-asserted-by":"publisher","first-page":"3388","DOI":"10.1002\/sim.5753","article-title":"A tutorial on propensity score estimation for multiple treatments using generalized boosted models","volume":"32","author":"McCaffrey","year":"2013","journal-title":"Stat Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10822-011-9505-2","article-title":"Multiple imputation with diagnostics (mi) in R: opening windows into the black box","volume":"45","author":"Su","year":"2011","journal-title":"J Stat Softw."},{"key":"B21","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1113\/expphysiol.2007.040048","article-title":"The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice","volume":"93","author":"Imai","year":"2008","journal-title":"Exp Physiol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e016219","DOI":"10.1161\/JAHA.120.016219","article-title":"Coronavirus disease 2019 (COVID-19) and cardiovascular disease: a viewpoint on the potential influence of angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 infection","volume":"9","author":"Guo","year":"2020","journal-title":"J Am Heart Assoc."},{"key":"B23","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1097\/SHK.0000000000000302","article-title":"Angiotensin-converting enzyme inhibition attenuates lipopolysaccharide-induced lung injury by regulating the balance between angiotensin-converting enzyme and angiotensin-converting enzyme 2 and inhibiting mitogen-activated protein kinase activation","volume":"43","author":"Li","year":"2015","journal-title":"Shock."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e4260","DOI":"10.1136\/bmj.e4260","article-title":"Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis","volume":"345","author":"Caldeira","year":"2012","journal-title":"BMJ."},{"key":"B25","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s11427-020-1643-8","article-title":"Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury","volume":"63","author":"Liu","year":"2020","journal-title":"Sci China Life Sci."},{"key":"B26","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1080\/22221751.2020.1746200","article-title":"Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension","volume":"9","author":"Meng","year":"2020","journal-title":"Emerg Microbes Infect."},{"key":"B27","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1093\/cid\/ciaa492","article-title":"Clinical impact of renin-angiotensin system inhibitors on in-hospital mortality of patients with hypertension hospitalized for COVID-19","volume":"155","author":"Tedeschi","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1056\/NEJMoa2008975","article-title":"Renin-angiotensin-aldosterone system inhibitors and risk of covid-19","volume":"382","author":"Reynolds","year":"2020","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/S0140-6736(20)31030-8","article-title":"Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study","volume":"395","author":"de","year":"2020","journal-title":"Lancet."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1056\/NEJMoa2006923","article-title":"Renin-angiotensin-aldosterone system blockers and the risk of Covid-19","volume":"382","author":"Mancia","year":"2020","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2000547","DOI":"10.1183\/13993003.00547-2020","article-title":"China medical treatment expert group for: comorbidity and its impact on 1590 patients with Covid-19 in China: a nationwide analysis","volume":"55","author":"Guan","year":"2020","journal-title":"Eur Respir J"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1161\/HYPERTENSIONAHA.120.15572","article-title":"Decreased mortality of COVID-19 with renin-angiotensin-aldosterone system inhibitors therapy in patients with hypertension: a meta-analysis","volume":"76","author":"Guo","year":"2020","journal-title":"Hypertension"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1164\/rccm.202002-0445OC","article-title":"COVID-19 with different severity: a multi-center study of clinical features","volume":"201","author":"Feng","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2000562","DOI":"10.1183\/13993003.00562-2020","article-title":"Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicenter) and outside Hubei (non-epicenter): a nationwide analysis of China","volume":"55","author":"Liang","year":"2020","journal-title":"Eur Respir J"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e205619","DOI":"10.1001\/jamanetworkopen.2020.5619","article-title":"Clinical characteristics of patients who died of coronavirus disease 2019 in China","volume":"3","author":"Xie","year":"2020","journal-title":"JAMA Netw Open."},{"key":"B36","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/joim.13063","article-title":"Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19)","volume":"288","author":"Wu","year":"2020","journal-title":"J Intern Med."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.577398\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T05:22:49Z","timestamp":1622438569000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.577398\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,31]]},"references-count":36,"alternative-id":["10.3389\/fcvm.2021.577398"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2021.577398","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,31]]},"article-number":"577398"}}